Preparation for developing a successor to the claims processing computer system for dispensing pharmacies
First written in FY2016. 5 of 7 entries say "Restated". Latest entry: FY2018-Q3.
No other company in this theme has enough history to compare yet.
- FY2018-Q3ReframedAnnual report
「Regarding the successor to “PHARMACY ACE,” the claims processing computer system for dispensing pharmacies in the pharmaceuticals and related network business, there is nothing to report because it does not meet the definition of research and development under the Accounting Standard for Research and Development Costs.」
The description changed from the previous explanation of “preliminary information-gathering activities” to stating that there is nothing applicable as a research and development activity because the successor does not constitute research or development under the Accounting Standard for Research and Development Costs. It does not state that development itself has been discontinued. - FY2018-Q2RestatedAnnual report
「During the cumulative consolidated second quarter, research and development activities at 株式会社システム・フォー in the pharmaceuticals and related network business consisted of gathering preliminary information for developing a successor to the existing claims processing computer system for dispensing pharmacies, “PHARMACY ACE.” Accordingly, no research and development expenses were incurred during the cumulative consolidated second quarter.」
Preliminary information gathering for development of the successor system is continuing, but research and development expenses have still not been incurred. - FY2017RestatedAnnual report
「The company is gathering preliminary information for developing a successor to the existing claims processing computer system for dispensing pharmacies, “PHARMACY ACE.” Accordingly, no research and development expenses were incurred during the consolidated fiscal year.」
Preliminary information gathering for development of the successor system is continuing, but no research and development expenses have been incurred. - FY2017-Q3RestatedAnnual report
「During the cumulative consolidated third quarter, research and development activities at 株式会社システム・フォー in the pharmaceuticals and related network business consisted of gathering preliminary information for developing a successor to the existing claims processing computer system for dispensing pharmacies, “PHARMACY ACE.” Accordingly, no research and development expenses were incurred during the cumulative consolidated third quarter.」
Preliminary information gathering for development of the successor system is continuing, but research and development expenses have still not been incurred. - FY2017-Q2RestatedAnnual report
「During the cumulative consolidated second quarter, research and development activities at 株式会社システム・フォー in the pharmaceuticals and related network business consisted of gathering preliminary information for developing a successor to the existing claims processing computer system for dispensing pharmacies, “PHARMACY ACE.” Accordingly, no research and development expenses were incurred during the cumulative consolidated second quarter.」
Preliminary information gathering for development of the successor system is continuing, but no research and development expenses have been incurred. - FY2017-Q1RestatedAnnual report
「The company is gathering preliminary information for developing a successor to the existing claims processing computer system for dispensing pharmacies, “PHARMACY ACE.” Accordingly, no research and development expenses were incurred during the cumulative consolidated first quarter.」
Preliminary information gathering for the successor system is continuing, but no research and development expenses have been incurred. - FY2016First statedAnnual report
「The company is gathering preliminary information for developing a successor to the existing claims processing computer system for dispensing pharmacies, “PHARMACY ACE.”」
No research and development expenses have been incurred, but preparatory activities for the successor system are described.